

**The Diagnostic Significance of Human Patatin  
Like Phospholipase Domain Containing  
Protein 3, PNPLA3 versus Fibro scan in  
Nonalcoholic fatty liver disease (NAFLD)**

*Thesis*

*Submitted for Partial Fulfillment of M.D Degree in  
Internal Medicine*

*By*

**Eman Samir Sayed Hassan Khallaf**

*M.B.,B.Ch.,MSC*

*Ain Shames University*

*Under Supervision of*

**Prof.Dr.Hossam Eldin Abd Elaziz Mahmoud**

*Professor of Gastroenterology & Internal Medicine*

*Faculty of Medicine - Ain Shames University*

**Prof. Dr. Tarek Mohamed Youssef**

*Professor of of Gastroenterology & Internal Medicine*

*Faculty of Medicine - Ain Shames University*

**Prof. Dr.Moataz Mohamed Sayed**

*Professor of of Gastroenterology & Internal Medicine*

*Faculty of Medicine - Ain Shames University*

**Dr. Mohamed Osama Ali**

*Lecturer of of Gastroenterology & Internal Medicine*

*Faculty of Medicine - Ain Shames University*

*Faculty of Medicine  
Ain Shames University*

**2018**



## Acknowledgment

First thanks to **ALLAH** to whom I relate any success in achieving any work in my life.

I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Hossam Abd Elaziz Mahmoud**, Professor of Gastroenterology & Internal Medicine Faculty of Medicine - Ain Shames University for his meticulous supervision, kind guidance, valuable instructions and generous help.

Special thanks are due to **Prof. Dr. Tarek Mohamed Youssef**, Professor of of Gastroenterology & Internal Medicine Faculty of Medicine - Ain Shames University for his sincere efforts, fruitful encouragement.

I am deeply thankful to **Ass. Prof. Dr. Moataz Mohamed Sayed**, Professor of of Gastroenterology & Internal Medicine Faculty of Medicine - Ain Shames University for his great help, outstanding support, active participation and guidance.

I am also delighted to express my deepest gratitude and thanks to **Dr. Mohamed Osama Ali**, Lecturer of of Gastroenterology & Internal Medicine Faculty of Medicine - Ain Shames University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.

**Eman Samir Sayed**

# Dedication

*Special thanks to my **Mother** and **Father** for their supports and love. Without their help I wouldn't be here. And also, my lovely **Sister** and **Brother***

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿وَعَلَّمَكَ مَا لَمْ تَكُنْ تَعْلَمُ وَكَانَ

فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا﴾

صدق الله العظيم  
سورة النساء آية (١١٣)

# *List of Contents*

<b>Title</b>	<b>Page No.</b>
List of Tables .....	6
List of Figures .....	7
List of Abbreviations .....	10
Introduction .....	1
aim of the Work .....	17
Review of Literature	
▪ Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis .....	18
▪ Patatin Like Phospholipase Domain Containing Protein 3 (PNPLA3) .....	69
▪ Transient Elastography .....	96
Patients and Methods .....	108
Results .....	114
Discussion .....	127
Summary .....	134
Conclusion and Recommendations .....	137
References .....	138
Arabic Summary	

## *List of Tables*

Table No.	Title	Page No.
<b>Table (1):</b>	Nonalcoholic fatty liver disease and related definitions. ....	20
<b>Table (2):</b>	Clinical identification of the metabolic syndrome (scientific statement by the American Heart Association and National Heart, Lung, and Blood Institute in the United States). ....	28
<b>Table (3):</b>	Protocol for a comprehensive evaluation of suspected NAFLD patients .....	38
<b>Table (3):</b>	Distribution of Characteristics and clinical measurements in both groups. ....	115
<b>Table (4):</b>	Distribution of Steatosis grades in nonalcoholic fatty liver group measured by Fibroscan. ....	119
<b>Table (5):</b>	Distribution of fibrosis grades in nonalcoholic fatty liver group measured by fibroscan. ....	120
<b>Table (6):</b>	Correlation of Fibrosis grades as regard PNPLA3 in nonalcoholic fatty liver group. ....	121
<b>Table (7):</b>	Correlation of steatosis grades as regard PNPLA3 in nonalcoholic fatty liver group. ....	122
<b>Table (8):</b>	Correlation of clinical measurements as regard PNPLA3 in nonalcoholic fatty liver group. ....	123
<b>Table (9):</b>	ROC curve representing pnpla3 marker in relation to steatosis. ....	125
<b>Table (10):</b>	ROC curve representing pnpla3 marker in relation to fibrosis. ....	126

## *List of Figures*

Fig. No.	Title	Page No.
<b>Figure (1):</b>	Regional obesity/overweight data. ....	23
<b>Figure (2):</b>	Estimated prevalence of obesity (BMI > 25) in males aged 15+ (2010). ....	24
<b>Figure (3):</b>	Estimated prevalence of obesity (BMI > 25) in females aged 15+ (2010). ....	24
<b>Figure (4):</b>	Estimated prevalences of NAFLD and NASH. ....	26
<b>Figure (5):</b>	Risk factors and associated conditions. ....	28
<b>Figure (6):</b>	The “multi-hit” hypothesis for nonalcoholic steatohepatitis (NASH) . ....	30
<b>Figure (8):</b>	Diagnostic flow-chart to assess and monitor disease severity in the presence of suspected NAFLD and metabolic risk factors. 1Steatosis biomarkers. ....	40
<b>Figure (9):</b>	NASH Clinical Research Network histological scoring system . ....	52
<b>Figure (10):</b>	Normal liver . ....	53
<b>Figure (11):</b>	Fatty liver (steatosis) (ballooning) . ....	54
<b>Figure (12):</b>	Nash . ....	54
<b>Figure (13):</b>	Nash fibrosis . ....	55
<b>Figure (14):</b>	Cirrhosis (nodularity & scarring) . ....	55
<b>Figure (15):</b>	Elements of a comprehensive lifestyle approach to NAFLD treatment. ....	58
<b>Figure (16):</b>	Summary for treatment options for NAFLD, NASH . ....	67
<b>Figure (17):</b>	Summary of up coming drugs . ....	68
<b>Figure (18):</b>	Commonality between the largest genome-wide association studies (GWASs) in nonalcoholic fatty liver disease (NAFLD). ....	74

## *List of Figures cont...*

Fig. No.	Title	Page No.
<b>Figure (19):</b>	Simplified schematic model showing the hypothetical molecular mechanism by which the <i>PNPLA3</i> I148M variant participates in the development and progression of nonalcoholic fatty liver fibrosis.....	79
<b>Figure (20):</b>	Hypothetical mechanism of hepatic fat accumulation associated with the 148 Isoleucine to Methionine protein variant patatin-like phospholipase domain-containing 3 polymorphism .....	80
<b>Figure (21):</b>	<i>PNPLA3</i> -associated steatohepatitis (PASH) phenotypes associated with variant <i>PNPLA3</i> .....	92
<b>Figure (22):</b>	Evaluation of incidentally discovered steatosis .....	93
<b>Figure (23):</b>	The probe of the Fibroscan device is positioned in an intercostal space near the right lobe of the liver, and a 50-MHz wave is passed into the liver from a small transducer on the end of the probe .....	99
<b>Figure (24):</b>	The characteristic of the new S and XL probes comparing to M probe.....	107
<b>Figure (25):</b>	Nafld group versus Control group as regard age (yrs) showing significant difference in age in NAFLD group with mean (48.58) versus in control group with mean (42.30).....	117
<b>Figure (26):</b>	Nafld group versus Control group as regard AST(U/L) showing significant increased AST in NAFLD patients with mean (28.59) versus control group (20.74).....	117
<b>Figure (27):</b>	Nafld group versus Control group as regard <i>PNPLA3</i> (µg/ml) showing significant increased expression of <i>PNPLA3</i> in NAFLD patients with mean (3.32) versus in control subjects with mean (1.65). .....	118

*List of Figures cont...*

Fig. No.	Title	Page No.
<b>Figure (28):</b>	Nafld group versus Control group as regard CAP (Controlled attenuation parameter) (dB/m) showing significant increased CAP values in NAFLD patients with mean (251.08) versus control group with mean (183.65).....	118
<b>Figure (29):</b>	Distribution of Steatosis grades in nonalcoholic fatty liver group. ....	119
<b>Figure (30):</b>	Distribution of Fibrosis grades in nonalcoholic fatty liver group.....	120
<b>Figure (31):</b>	Correlation of Fibrosis grades as regard PNPLA3 in nonalcoholic fatty liver group. ....	121
<b>Figure (32):</b>	Correlation of Steatosis grades as regard PNPLA3 in nonalcoholic fatty liver group. ....	122
<b>Figure (33):</b>	ROC curve representing pnpla3 marker in relation to steatosis between grade (0,1,2) and (3).....	125
<b>Figure (34):</b>	ROC curve representing pnpla3 marker in relation to fibrosis between grade (0,1) and (2,3,4).....	126

---

---

## List of Abbreviations

---

---

Abb.	Full term
AASLD.....	<i>American association for the study of liver diseases</i>
ACEI .....	<i>Angiotensin converting enzyme inhibitor</i>
ALD.....	<i>Alcoholic liver disease</i>
ALT.....	<i>Alanine amino transferase</i>
ANA .....	<i>Antinuclear antibody</i>
ARB.....	<i>angiotensin receptor blockers</i>
ASMA.....	<i>Anti smooth muscle antibody</i>
AST.....	<i>Aspartate amino transferase</i>
BASH.....	<i>Both alcoholic and nonalcoholic steatohepatitis</i>
BMI.....	<i>Body mass index</i>
CAP.....	<i>controlled attenuation parameter</i>
CASH.....	<i>chemotherapy-associated steatohepatitis</i>
CHB .....	<i>Chronic hepatitis B virus</i>
CHC .....	<i>Chronic hepatitis C virus</i>
CHOL.....	<i>Cholesterol</i>
CKD .....	<i>Chronic kidney disease</i>
CT .....	<i>computed tomography</i>
CVD .....	<i>Cardiovascular disease</i>
DASH.....	<i>Drug -associated steatohepatitis</i>
EASD- .....	<i>European association for study of diabetes</i>
EASL .....	<i>European association for study of liver</i>
EASO .....	<i>European association for study of obesity</i>
e-GFR.....	<i>Estimated – glomerular filtration rate</i>
ELF .....	<i>European Liver Fibrosis</i>
FBG.....	<i>Fasting blood glucose</i>
FDA.....	<i>Food and drug administration</i>
FFA.....	<i>Free fatty acids</i>

---

---

## List of Abbreviations cont...

---

---

Abb.	Full term
<i>GGT</i> .....	<i>Gamma glutamyl transferase</i>
<i>GWAS</i> .....	<i>Genome-wide association studies</i>
<i>HA</i> .....	<i>Hyaluronic acid</i>
<i>HBV</i> .....	<i>Hepatitis B virus</i>
<i>HCV</i> .....	<i>Hepatitis C virus</i>
<i>HDL</i> .....	<i>Low high-density lipoprotein</i>
<i>Hh</i> .....	<i>Hedgehog</i>
<i>HIF</i> .....	<i>Hypoxia inducible factors</i>
<i>HSCs</i> .....	<i>Hepatic stellate cells</i>
<i>IFG</i> .....	<i>Impaired fasting glucose</i>
<i>IH</i> .....	<i>Intermittent hypoxia</i>
<i>IH</i> .....	<i>Intermittent hypoxia</i>
<i>IL</i> .....	<i>Interleukin</i>
<i>IR</i> .....	<i>Insulin resistance</i>
<i>LDL</i> .....	<i>Low-density lipoprotein</i>
<i>LSM</i> .....	<i>Liver stiffness measurement</i>
<i>MetS</i> .....	<i>Metabolic syndrome</i>
<i>MRI</i> .....	<i>Magnetic resonance imaging</i>
<i>MRI</i> .....	<i>Magnetic resonance imaging</i>
<i>mRNA</i> .....	<i>Messenger ribonucleic acid</i>
<i>NAFLD</i> .....	<i>Nonalcoholic fatty liver disease</i>
<i>NAS</i> .....	<i>NAFLD Activity Score</i>
<i>NASH</i> .....	<i>Nonalcoholic steatohepatitis</i>
<i>NFS</i> .....	<i>NAFLD fibrosis score</i>
<i>NPV</i> .....	<i>Negative predictive value</i>
<i>OSA</i> .....	<i>Obstructive sleep apnea</i>
<i>P3NP</i> .....	<i>Peptide of pro-collagen III</i>
<i>PASH</i> .....	<i>PNPLA3-associated steatohepatitis</i>

---

---

---

## *List of Abbreviations cont...*

---

---

<b>Abb.</b>	<b>Full term</b>
<i>PNPLA</i> .....	<i>Patatin-like phospholipase domain-containing protein</i>
<i>PPV</i> .....	<i>Positive predictive value</i>
<i>RAAS</i> .....	<i>Renin-Angiotensin-Aldosterone System</i>
<i>RCTs</i> .....	<i>Randomized controlled trials</i>
<i>SOS</i> .....	<i>Swedish obese subjects</i>
<i>SS</i> .....	<i>Simple steatosis</i>
<i>TE</i> .....	<i>Transient elastography</i>
<i>TG</i> .....	<i>Triglycerides</i>
<i>TIMP</i> .....	<i>Tissue inhibitor of metalloproteinase</i>
<i>TNF</i> .....	<i>Tumor necrosis factor</i>
<i>TNF</i> .....	<i>Tumour necrosis factor-alpha</i>
<i>TZD</i> .....	<i>Thiazolidinediones</i>
<i>UDCA</i> .....	<i>Ursodeoxycholic acid</i>
<i>US</i> .....	<i>Ultrasonography</i>
<i>VEGF</i> .....	<i>Vascular endothelial growth factor</i>
<i>WGO</i> .....	<i>World Gastroenterology Organisation</i>
<i>WHO</i> .....	<i>World Health Organization</i>

## INTRODUCTION

**N**on alcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver function test results in both adults and children (*Angulo, 2002; Wieckowska and Feldstein, 2005*).

The prevalence of NAFLD in obese patients is approximately 70% and has become the most common liver disorder in Western countries (*Lazo and Clark, 2008*).

Accompanying an increase in the prevalence of obesity, the disease burden of NAFLD is also increasing in Eastern countries (*Hsiao et al., 2007; Hsieh et al., 2009*).

NAFLD in fact covers a histological spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis (*Angulo, 2002; Argo and Caldwell, 2009*).

Simple steatosis without fibrosis or inflammation has a benign clinical course in most but not in all cases without excess mortality (*Ekstedt et al., 2006*).

NASH, on the other hand, may have a more progressive course that can lead to cirrhosis in 10-15% of patients (*Xie et al., 2012*).

Survival is lower in patients with NASH based on the findings from long-term longitudinal studies (*Ekstedt et al., 2006; Soderberg et al., 2010*).

It is therefore imperative to distinguish simple steatosis from NASH in order to provide risk stratification and intervention slowing down disease progression for patients with the latter condition (*Wieckowska et al., 2007*).

Liver biopsy remains the gold standard for making the diagnosis of NASH. However, this procedure is invasive, costly, and is associated with rare but potential complications and sampling errors. Hence it is not suitable as a screening tool for a condition that affects one-third of the American population (*Wieckowska et al., 2007*).

Imaging studies such as ultrasonography, computed tomography (CT), and magnetic resonance imaging have been used to diagnose NAFLD (*Rotman et al., 2010*).

These modalities have the advantages of being noninvasive and can be repetitively performed over a period of time (*Rotman et al., 2010*).

Nevertheless, none of them have sufficient sensitivity and specificity for staging the disease and cannot distinguish between simple steatosis and NASH with or without fibrosis (*Wieckowska et al., 2007*).

Transient elastography (FibroscanR) is a new technique that allows rapid, non-invasive measurement of mean tissue stiffness, which has been shown to be useful for accurate estimation of hepatic fibrosis (*Moreno-Otero et al., 2006*).

Guidelines from the national institute of health and care excellence, the European Association of the study of liver, and the Asian Pacific Association for the study of liver recommend using fibroscan technology for the initial evaluation of liver diseases (*Afdhal, 2012*).

Several biomarkers that are associated with inflammation, ECM, and apoptosis have been individually studied for their performances in distinguishing NASH from simple steatosis, and Through the use of genome wide association studies, several genetic factors have recently been shown to be associated with NAFLD (*Pearce et al., 2013*).

Romeo et al demonstrated that an allele of patatin-like phospholipase domain-containing protein3 (PNPLA3, rs738409 C/G, encoding I148M) is associated with an increased liver fat content (*Romeo et al., 2008*)

The PNPLA3 rs738409variant has also been found to be associated with histologic disease severity of NAFLD, including steatosis, NASH, and fibrosis (*Sookoian et al., 2009; Valenti et al., 2010; Rotman et al., 2010; Sookoian and Pirola, 2011; Hotta et al., 2010*).